Market Research Logo

Influenza B Infections - Pipeline Review, H2 2015

Influenza B Infections - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Influenza B Infections - Pipeline Review, H2 2015’, provides an overview of the Influenza B Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Influenza B Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza B Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Influenza B Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Influenza B Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Influenza B Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Influenza B Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Influenza B Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Influenza B Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Influenza B Infections Overview
Therapeutics Development
Pipeline Products for Influenza B Infections - Overview
Pipeline Products for Influenza B Infections - Comparative Analysis
Influenza B Infections - Therapeutics under Development by Companies
Influenza B Infections - Therapeutics under Investigation by Universities/Institutes
Influenza B Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Influenza B Infections - Products under Development by Companies
Influenza B Infections - Products under Investigation by Universities/Institutes
Influenza B Infections - Companies Involved in Therapeutics Development
AltraVax Inc.
Aphios Corporation
Chimerix, Inc.
ContraFect Corporation
Crucell N.V.
Hanmi Pharmaceuticals, Co. Ltd.
Humabs BioMed SA
Mucosis B.V.
Novartis AG
REPLICor Inc.
Vaxart, Inc.
Influenza B Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AL-18 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APP-0205 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APP-309 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CF-403 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR-8033 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR-8071 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR-9114 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FluGEM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HIP-1403 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [serotype B] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strain B/yamagata] (monovalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody for Influenza B Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REP-9 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Influenza B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Influenza B Infections - Recent Pipeline Updates
Influenza B Infections - Dormant Projects
Influenza B Infections - Product Development Milestones
Featured News & Press Releases
Mar 11, 2011: Sanofi Pasteur And Daiichi Sankyo Announce Voluntary Recall Of Hemophilus Influenza Type B Conjugate Vaccine
Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Influenza B Infections, H2 2015
Number of Products under Development for Influenza B Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Influenza B Infections - Pipeline by AltraVax Inc., H2 2015
Influenza B Infections - Pipeline by Aphios Corporation, H2 2015
Influenza B Infections - Pipeline by Chimerix, Inc., H2 2015
Influenza B Infections - Pipeline by ContraFect Corporation, H2 2015
Influenza B Infections - Pipeline by Crucell N.V., H2 2015
Influenza B Infections - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
Influenza B Infections - Pipeline by Humabs BioMed SA, H2 2015
Influenza B Infections - Pipeline by Mucosis B.V., H2 2015
Influenza B Infections - Pipeline by Novartis AG, H2 2015
Influenza B Infections - Pipeline by REPLICor Inc., H2 2015
Influenza B Infections - Pipeline by Vaxart, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Influenza B Infections Therapeutics - Recent Pipeline Updates, H2 2015
Influenza B Infections - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Influenza B Infections, H2 2015 9
Number of Products under Development for Influenza B Infections - Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 13
Comparative Analysis by Early Stage Products, H2 2015 15
Assessment by Monotherapy Products, H2 2015 29
Assessment by Combination Products, H2 2015 30
Number of Products by Top 10 Targets, H2 2015 31
Number of Products by Stage and Top 10 Targets, H2 2015 31
Number of Products by Top 10 Mechanism of Actions, H2 2015 33
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 33
Number of Products by Top 10 Routes of Administration, H2 2015 35
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 35
Number of Products by Top 10 Molecule Types, H2 2015 37
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report